Cardiovascular disease (CVD), coronary heart disease (CHD) and stroke are responsible for 16.7 million, or 29.9% of total global deaths associated with some type of disease, according to the World Health Organization. The diagnosis, care and treatment of CVD patients is measured in the hundreds of billions of dollars. By 2010, CVD will be the leading cause of death in developing countries.

Gamma Therapeutics’ flaghsip product, the GammaCoeur Cardiovascular Disease Risk Assay, will be a new heart attack and stroke risk assay designed to complement traditional assays in use today, such as cholesterol, considered by many to be the gold standard. GammaCoeur will be targeted to primary care physicians, cardiologists, and hematologists who order diagnostic testing to assess whether or not their patients currently have or are at risk of cardiovascular disease and, therefore, fall into in a heart attack or stroke risk group.  Upon FDA Office of InVitro Diagnostic Device (OIVD) approval, slated for 2012-2013, GammaCoeur will be sold indirectly through strategic partner and channel sales relationships to private, public and independent diagnostic labs globally.

Revenue Opportunity

In the U.S. alone, $506 B is spent annually on heart disease, including physician visits, treatment, drugs, diagnostics, hospitalization and surgeries.  Approximately $1.36 B of this total represents spending on diagnostic testing. GammaCoeur could provide a complementary CVD biomarker risk assay that potentially could capture 10% of this market for total revenues of >$136 M by 2016.

Funding: Gamma Therapeutics is currently funded with a 3-year NIH/SBIR development grant in the amount of $1.46 M.

For business and financial information, please contact: David Eastman, Chief Executive Officer,

Copyright © 2010, Gamma Therapeutics, Inc. All rights reserved.